The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Epizyme
Research Funding - Epizyme
Health care cost impact associated with adverse events (AEs) among treatments in third-line+ (3L+) relapsed/refractory follicular lymphoma (R/R FL).
 
Sameh Gaballa
No Relationships to Disclose
 
Moshe Y. Levy
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Epizyme; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; MorphoSys; Seagen; Takeda
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Epizyme; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; MorphoSys; Seagen; Takeda
 
Michael Keith
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme; Sage Therapeutics
 
Alex Wong
Employment - Abbvie (I); Analysis Group
Stock and Other Ownership Interests - Abbvie (I)
 
David Proudman
Employment - Analysis Group
 
Dave Nellesen
Employment - Analysis Group
 
Khalid Mamlouk
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme